Market
Highest customer satisfaction rating for liraglutide medication in Brazil in 2025?
2
Resolution / Starting Odds
Ozempic • 25%
Lirux • 25%
Olire • 25%
Other • 25%
Consumer satisfaction surveys and reports published by healthcare organizations
Story
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Similar markets
AstraZeneca • 25%
Novo Nordisk • 25%
Other • 25%
Eli Lilly • 25%
Ozempic • 25%
Mounjaro • 25%
Wegovy • 25%
Other GLP-1 drug • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Ozempic • 25%
Mounjaro • 25%
Wegovy • 25%
No significant change • 25%
Less favorable • 25%
More favorable • 25%
Divided opinion • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Eli Lilly > 60% • 25%
Obesity • 25%
Alzheimer's Disease • 25%
Other • 25%
Type 2 Diabetes • 25%
Somewhat positive • 25%
Negative • 25%
Neutral • 25%
Highly positive • 25%